Pre-booster and post-booster seroprevalence of measles antibodies among employees of the Olomouc University Hospital – a pilot study
Authors:
Lad. Štěpánek 1; R. Večeřová 2; P. Sauer 2; Lub. Štěpánek 3; M. Kolář 2
; M. Nakládalová 1
Authors place of work:
Klinika pracovního lékařství, Lékařská fakulta Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc
1; Ústav mikrobiologie, Lékařská fakulta Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc
2; Ústav biofyziky a informatiky, 1. lékařská fakulta Univerzity Karlovy, Praha
3
Published in the journal:
Epidemiol. Mikrobiol. Imunol. 70, 2021, č. 2, s. 104-109
Category:
Original Papers
Summary
Introduction: The increase in measles cases in early 2019 led to the implementation of several preventive measures focused mainly on health care providers. The study aimed to evaluate the seroprevalence of measles antibodies among employees of a large hospital and, a year apart, the rate of seroconversion in a pilot sample of the revaccinated subjects.
Methods: In 3027 employees of the University Hospital Olomouc, specific immunoglobulin G levels were tested on a voluntary basis. Those with insufficient levels were offered a booster dose. About approximately one year after the booster dose, the same test was performed in a sample of 52 employees.
Results: Of the tested subjects with a mean age of 41.8 ± 9.2 years, 54.0% were seropositive. A higher proportion of seropositivity as well as higher absolute values of antibody titers were noted in those born before routine vaccination was introduced in 1969. A total of 80.9% of the seronegative subjects opted for a booster dose. Seroconversion occurred in 73.2% of retested subjects. The relative increase of post-booster antibody titers was moderately correlated with age (r = 0.47, p < 0.05).
Conclusion: The proportion of seronegative employees of a large hospital reached 46.0%, being higher in younger individuals. Seroconversion occurred in 73.2% of booster dose recipients included in a pilot sample for reanalysis. A statistically significant correlation was noted between the relative increase of antibody titers and age.
Keywords:
measles – booster dose – seroprevalence – seroconversion
Zdroje
1. Státní zdravotní ústav. 50 let očkování proti spalničkám v ČR [online]. 2019-08-30 [cit. 2020-11-04]. Dostupné na www: http://www.szu.cz/tema/prevence/50-let-ockovani-proti- -spalnickam-v-cr.
2. Trmal J, Limberková R. Vyhodnocení epidemie spalniček v Ústeckém kraji. Epidemiol Mikrobiol Imunol, 2015;64(3):139–145.
3. Hygienická stanice hlavního města Prahy. V Praze letos prozatím spalničkami onemocněla rovná stovka lidí [online]. 2018-12-20 [cit. 2021-01-17]. Dostupné na www: http://www.hygpraha.cz/ dokumenty/spalnicky-2018-vyskyt-3980_3980_37_1.html?fbclid= IwAR39xMQgoc9ZuVHt1iUj8R5AmO30WdBV6LOcf3M- -L8Zvg-bMe5IopGoAcpA.
4. World Health Organization. WHO EpiData [online]. 2020 [cit. 2020-11-04]. Dostupné na www: https://www.euro.who.int/en/ health-topics/disease-prevention/vaccines-and-immunization/ publications/surveillance-and-data/who-epidata.
5. Nicolay N, Mirinaviciute G, Mollet T, et al. Epidemiology of measles during the COVID-19 pandemic, a description of the surveillance data, 29 EU/EEA countries and the United Kingdom, January to May 2020. Euro Surveill, 2020;25(31):2001390.
6. Hotez PJ. Anti-science extremism in America: escalating and globalizing. Microbes Infect, 2020;S1286–4579(20)30158-1.
7. Hughes SL, Bolotin S, Khan S, et al. The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness – a systematic review. Vaccine, 2020;38(3):460–469.
8. World Health Organization. Immunization, vaccines and biologicals [online]. 2020-01 [cit. 2020-11-04]. Dostupné na www: https://www.who.int/immunization/diseases/measles/en.
9. Fabiánová K, Manďáková Z, Lexová P, et al. Souhrn aktuálních poznatků v prevenci onemocnění spalničkami; doporučení Advisory Committee on Immunization Practices (ACIP) v kontextu současné epidemiologické situace v ČR. Zprávy centra epidemiologie a mikrobiologie (SZÚ, Praha), 2018;27(5):110–112.
10. Štěpánek L, Nakládalová M, Boriková A, et al. Measles immunity in a Czech tertiary care hospital. Vaccine, 2020;38(14):2889–2892.
11. Ministerstvo zdravotnictví České republiky. Opatření ministra zdravotnictví ke zvýšení proočkovanosti proti spalničkám u zdravotnických pracovníků [online]. 2019-02-22 [cit. 2020-11-04]. Dostupné na www: https://www.mzcr.cz/tiskove-centrum-mz/ opatreni-ministra-zdravotnictvi-ke-zvyseni-proockovanosti- -proti-spalnickam-u-zdravotnickych-pracovniku.
12. Coppeta L, Pietroiusti A, Lieto P, et al. Measles immunity in an Italian teaching hospital. Occup Med (Lond), 2019;69(2):143–145.
13. Ledda C, Cinà D, Garozzo SF, et al. Vaccine-preventable disease in healthcare workers in Sicily (Italy): seroprevalence against measles. Future Microbiol, 2019;14:33–36.
14. Jung J, Kim SK, Kwak SH, et al. Seroprevalence of measles in healthcare workers in South Korea. Infect Chemother, 2019;51(1):58–61.
15. Liu CP, Lu HP, Luor T. Observational study of a new strategy and management policy for measles prevention in medical personnel in a hospital setting. BMC Infect Dis, 2019;19(1):551.
16. Yang L, Grenfell BT, Mina MJ. Waning immunity and re-emergence of measles and mumps in the vaccine era. Curr Opin Virol, 2020;40:48–54.
17. Ministerstvo zdravotnictví České republiky. Rizika onemocnění spalničkami a možnosti prevence [online]. 2019-04-08 [cit. 2021- 01-17]. Dostupné na www: https://www.mzcr.cz/rizika-onemocneni- spalnickami-a-moznosti-prevence/.
18. Kennedy RB, Ovsyannikova IG, Thomas A, et al. Differential durability of immune responses to measles and mumps following MMR vaccination. Vaccine, 2019;37(13): 1775–1784.
19. LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc, 2007;161(3):294– 301.
20. Chang HH, Kim SW, Kwon KT, et al. Preliminary report of seroprevalence of anti-measles immunoglobulin G among healthcare workers of 6 teaching hospitals of Daegu, Korea in 2019. Infect Chemother, 2019;51(1):54–57.
21. Malinová J, Petráš M, Čelko AM. A Serosurvey identifying vulnerability to measles in health care workers. A hospital-based prospective seroprevalence study. Int J Environ Res Public Health, 2020;17(12):4219.
22. Fleischmannová J, Šimečková E. Séroprevalence IgG protilátek proti spalničkám u zaměstnanců Nemocnice Strakonice, a.s. Epidemiol Mikrobiol Imunol, 2020;69(3):121–126.
23. Bianchi FP, Stefanizzi P, De Nitto S, et al. Long-term immunogenicity of measles vaccine: an Italian retrospective cohort study. J Infect Dis, 2020;221(5):721–728.
24. Griffin DE. Measles immunity and immunosuppression. Curr Opin Virol, 2020;46:9–14.
25. Ayasoufi K, Pfaller CK. Seek and hide: the manipulating interplay of measles virus with the innate immune system. Curr Opin Virol, 2020;41:18–30.
Štítky
Hygiene and epidemiology Medical virology Clinical microbiologyČlánok vyšiel v časopise
Epidemiology, Microbiology, Immunology
2021 Číslo 2
Najčítanejšie v tomto čísle
- Non-O1/non-O139 vibrios – occurrence not only in Europe in recent years
- Borrelia miyamotoi – another emerging tick-borne pathogen
- Substance use and addictive behaviours during COVID-19 confinement measures increased in intensive users: Results of an online general population survey in the Czech Republic
- Pre-booster and post-booster seroprevalence of measles antibodies among employees of the Olomouc University Hospital – a pilot study